Galectin Therapeutics is working to improve the lives of patients with NASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE Phase 2b/3 study in NASH cirrhosis.
News
-
10/15/24
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting -
09/30/24
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference -
09/03/24
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Who We Are
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Learn MoreWhat We Do
Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
Learn MoreWho We Help
The lead development program is in non‑alcoholic steatohepatitis (NASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Learn More